Sandra Jacobson, MD, has no disclosures to report.

James M. Ellison, MD, (peer/content reviewer) has disclosed that he received research support from Eli Lilly and Company.


1. Toornvliet R, van Berckel BN, Luurtsema G, et al. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther. 2006;79:540-548.

2. Bartels AL, Kortekaas R, Bart J, et al. Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol Aging. 2009;30:1818-1824.

3. Greenblatt DJ, Sellers EM, Shader RI. Drug therapy: drug disposition in old age. N Engl J Med. 1982;306:1081-1088.

4. Thompson TL 2nd, Moran MG, Nies AS. Drug therapy: psychotropic drug use in the elderly: Part 1. N Engl J Med. 1983;308:134-138.

5. Wynn GH, Oesterheld JR, Cozza KL, Armstrong SC. Clinical Manual of Drug Interaction Principles for Medical Practice. Washington, DC: American Psychiatric Publishing, Inc; 2009.

6. Beaulieu JM, Gainetdinov RR, Caron MG. Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol. 2009;49:327-347.

7. Bowie MW, Slattum PW. Pharmacodynamics in older adults: a review. Am J Geriatr Pharmacother. 2007;5:263-303.

8. Jacobson SA, Pies RW, Katz IR. Clinical Manual of Geriatric Psychopharmacology. Washington, DC: American Psychiatric Publishing, Inc; 2007.

9. Oesterheld J. P-glycoprotein (PGP) table—the effect of drugs and foods. http://www.genemedrx.com/PGPtable.php. Accessed December 18, 2012.

10. Flockhart DA. P450 Drug interaction table: abbreviated “clinically relevant” table. http://medicine.iupui.edu/clinpharm/ddis/ClinicalTable.aspx. Accessed December 18, 2012.